Similarly, TKIs targeting vascular endothelial growth factor receptor (VEGFR), such as sorafenib and sunitinib, are used to treat renal cell carcinoma and hepatocellular carcinoma by inhibiting angiogenesis, a process essential for tumor growth and metastasis [60]. The gene discussed is KDR; the disease is neoplasm.